Beyond Single Nucleotide Polymorphisms: CYP3A5∗3∗6∗7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White …
DA Brazeau, K Attwood, CJ Meaney, GE Wilding… - Frontiers in …, 2020 - frontiersin.org
Interpatient variability in tacrolimus pharmacokinetics is attributed to metabolism by
cytochrome P-450 3A5 (CYP3A5) isoenzymes and membrane transport by P-glycoprotein …
cytochrome P-450 3A5 (CYP3A5) isoenzymes and membrane transport by P-glycoprotein …
CYP3A5 and CYP3A4, but not ABCB1 Polymorphisms Affect Tacrolimus Dose-Adjusted Trough Concentrations in Kidney Transplant Recipients
M Kurzawski, J Dąbrowska, K Dziewanowski… - …, 2014 - Taylor & Francis
Background: Tacrolimus (TAC), acting as a calcineurin inhibitor, is an immunosuppressant
widely used after kidney transplantation. TAC requires blood concentration monitoring due …
widely used after kidney transplantation. TAC requires blood concentration monitoring due …
Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation
G Gervasini, M Garcia, RM Macias… - Transplant …, 2012 - Wiley Online Library
We retrospectively examined the association of polymorphisms in the CYP3A, CYP2J2,
CYP2C8, and ABCB1 genes with pharmacokinetic (PKs) and pharmacodynamic (PDs) …
CYP2C8, and ABCB1 genes with pharmacokinetic (PKs) and pharmacodynamic (PDs) …
CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study
V Haufroid, P Wallemacq… - American journal of …, 2006 - Wiley Online Library
Genetic polymorphisms in biotransformation enzyme CYP3A5 (6986G> A, CYP3A5* 3;
14690A> G, CYP3A5* 6) and drug transporter ABCB1 (1236C> T; 2677G> T/A; 3435C> T) …
14690A> G, CYP3A5* 6) and drug transporter ABCB1 (1236C> T; 2677G> T/A; 3435C> T) …
Influence of Different Allelic Variants of the CYP3A and ABCB1 Genes on the Tacrolimus Pharmacokinetic Profile of Chinese Renal Transplant Recipients
CY Cheung, RAM Op den Buijsch… - …, 2006 - Taylor & Francis
Tacrolimus has a narrow therapeutic window and a wide interindividual variation in its
pharmacokinetics. The cytochrome P450 3A (C YP3A) and the ATP-binding cassette B1 …
pharmacokinetics. The cytochrome P450 3A (C YP3A) and the ATP-binding cassette B1 …
Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype
T Vanhove, P Annaert, D Lambrechts… - The Pharmacogenomics …, 2017 - nature.com
The relevance of most genetic polymorphisms beyond CYP3A5* 1 on tacrolimus disposition
remains unclear. We constructed a predictive mixed model for tacrolimus dose-corrected …
remains unclear. We constructed a predictive mixed model for tacrolimus dose-corrected …
Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients
M Miura, S Satoh, H Kagaya, M Saito… - …, 2011 - Taylor & Francis
Aim: Tacrolimus is a substrate of CYP3A4 and CYP3A5. The present study investigated the
impact of the CYP3A4* 1/* 1G polymorphism compared with CYP3A5 genotypes on the …
impact of the CYP3A4* 1/* 1G polymorphism compared with CYP3A5 genotypes on the …
Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients
DAC Cusinato, R Lacchini, EA Romao… - British journal of …, 2014 - Wiley Online Library
Aims Tacrolimus (TAC) is one of the most successful immunosuppressive drugs in
transplantation. Its pharmacokinetics (PK) and pharmacogenetics (PG) have been …
transplantation. Its pharmacokinetics (PK) and pharmacogenetics (PG) have been …
Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian …
WS Oetting, B Wu, DP Schladt, W Guan… - The …, 2018 - nature.com
The immunosuppressant tacrolimus (TAC) is metabolized by both cytochrome P450 3A4
(CYP3A4) and CYP3A5 enzymes. It is common for European Americans (EA) to carry two …
(CYP3A4) and CYP3A5 enzymes. It is common for European Americans (EA) to carry two …
CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation
F Glowacki, A Lionet, D Buob… - Nephrology Dialysis …, 2011 - academic.oup.com
Background. The effect of potentially relevant genetic polymorphisms, CYP3A5 6986A> G
and ABCB1 3435C> T, on Tacrolimus pharmacokinetics and graft clinical outcome was …
and ABCB1 3435C> T, on Tacrolimus pharmacokinetics and graft clinical outcome was …